Press release -
Sobi publishes Report for the Second Quarter 2014
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its results for the second quarter 2014. Revenues totalled SEK 662.5 M (520.2), an increase of 27 per cent with contribution from all areas of the portfolio. The 2014 outlook is unchanged.
Business Highlights Q2 2014
· Initiated direct sales of Orfadin® in North America
· Filed for EU approval of Xiapex® for Peyronie’s Disease
· Entered partnership with Tigenix for the commercialisation of ChondroCelect®
· Released positive topline phase-3 paediatric data regarding Eloctate™ from Kids A-LONG
· Eloctate approved by FDA
Financial Highlights Q2 2014 (Q2 2013)
· Total revenues were SEK 662.5 M (520.2)
· Product revenues were SEK 475.5 M (371.7)
· Gross margin was 61 per cent (61)
· EBITA was SEK 86.3 M (37.8)
· Ended the quarter with a cash position of SEK 503.2 M
“The second quarter marks a solid mid-year position for the company with balanced growth across the commercial portfolio“, said Geoffrey McDonough, CEO and President. “From a development perspective, our long-acting factors for haemophilia received several regulatory approvals in collaborator Biogen Idec’s territories, helping move these programmes into a pre-launch phase for the company, pending Sobi’s opt-in later this year.”
|
Financial Summary |
|||||||
|
Amounts in SEK M |
Q2 2014 |
Q2 2013 |
Change |
H1 2014 |
H1 2013 |
Change |
Full Year 2013 |
|
Total revenues |
662.5 |
520.2 |
27% |
1 235.8 |
1 048.7 |
18% |
2,176.7 |
|
Gross profit |
406.2 |
316.7 |
28% |
725.9 |
619.6 |
17% |
1,284.0 |
|
Gross margin |
61% |
61% |
59% |
59% |
59% |
||
|
EBITA |
86.3 |
37.8 |
>100% |
-201.5 |
99.0 |
<-100% |
211.0 |
|
EBITA excluding Kiobrina write-off |
86.3 |
37.8 |
>100% |
123.4 |
99.0 |
25% |
211.0 |
|
EBIT (Operating profit/loss) |
16.0 |
-31.9 |
>100% |
-342.0 |
-35.3 |
<-100% |
-66.6 |
|
Profit/loss for the period |
25.6 |
-10.9 |
>100% |
-303.1 |
-23.1 |
<-100% |
-93.0 |
Outlook 2014 unchanged
For 2014, Sobi continues to expect the company’s total revenues for the full year to be in the range of SEK 2,300 to 2,500 million. The gross margin is expected to be in the range of 58-60 per cent. In addition, the operating costs are expected to increase as the company continues to prepare for the planned launch of the haemophilia programmes.
Topics
- Health, Health Care, Pharmaceuticals
Categories
- q2 2014 results
- sobi
- haemophilia
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.
For more information please contact
Media relations
Oskar Bosson, Head of Communications
T: +46 70 410 71 80
oskar.bosson@sobi.com
Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com
